Research Article

Helicteric Acid, Oleanic Acid, and Betulinic Acid, Three Triterpenes from Helicteres angustifolia L., Inhibit Proliferation and Induce Apoptosis in HT-29 Colorectal Cancer Cells via Suppressing NF-κB and STAT3 Signaling

Dan Su,1 Yu-qiao Gao,2 Wei-bo Dai,2 Ying Hu,2 Yan-fen Wu,1 and Quan-xi Mei2

1College of Materials Science and Food Engineering, Zhongshan Institute, University of Electronic Science and Technology of China, Zhongshan, Guangdong 528400, China
2The Zhongshan Affiliated Hospital, Guangzhou University of Chinese Medicine, Zhongshan, Guangdong 528401, China

Correspondence should be addressed to Yu-qiao Gao; aqiaosky@163.com

Received 21 November 2016; Accepted 8 February 2017; Published 26 February 2017

Academic Editor: Luigi Ricciardiello

Copyright © 2017 Dan Su et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Colorectal cancer (CRC) is one of the most common malignancies and most frequent cause of cancer death worldwide. The activation of both NF-κB and STAT3 signaling and the crosstalk between them play an important role in colorectal tumor. Helicteres angustifolia L. is a type of commonly used Chinese medicinal herb and possesses a wide variety of biological activities. In the present study, we investigate the effects of three triterpenes from H. angustifolia (HT) such as helicteric acid (HA), oleanic acid (OA), and betulinic acid (BA), on inhibiting CRC progression. Our results showed that HT extracts could decrease proliferation and induce apoptosis in HT-29 colorectal cancer cells. Moreover, HT extracts could suppress LPS-triggered phosphorylation of IKK, IκB, and NF-κB, attenuate IL-6-induced phosphorylation of JAK2 and STAT3, and suppress the expression of c-Myc, cyclin-D1, and BCL-xL, the downstream gene targets of NF-κB and STAT3. Therefore, HT extracts showed potent therapeutic and antitumor effects on CRC via inhibiting NF-κB and STAT3 signaling.

1. Introduction

Colorectal cancer (CRC) is one of the most common malignant cancers worldwide [1–3], in particular in the developed western countries. However, at present its incidence is also increased in the developing countries, especially in China [4]. Although many improvements in chemotherapy and surgical techniques have been made, thus reducing CRC incidence and mortality rates, more than 20% of CRC patients are still associated with poor clinical outcomes [1, 5].

CRC initiation, malignant transformation, and progression are commonly associated with inflammation [6–8]. High levels of inflammatory markers have been usually detected in CRC patients. Interleukin- (IL-) 6 in the serum, for example, is detected in the majority of CRC patients and related to a remarkable high mortality [9, 10]. Recently, NF-κB and STAT3 activation were found to play very critical roles in CRC cell growth, survival, invasion, and migration [11–14].

The effects of natural products from plants have been investigated to a large extent on cancer cell proliferation, survival, invasion, and metastasis due to their bioactivities and diversity of chemical constituents [15–17]. Helicteres angustifolia L. (Sterculiaceae) (HT), known as “Shan-Zhi-Ma” in Chinese, one of the herbal medicines widely used in traditional medicine in southern China, has been reported to be effective in the treatment of influenza fever, bacterial infections, inflammation, and even cancer [18, 19].

The biological activities of many chemical compounds extracted from HT have been reported [18, 20]. HT and its triterpenes possess anti-inflammatory and antitumor effects in cancer cells, including colorectal tumor HT-29 cell [18, 21]. Triterpenes are considered as HT bioactive chemical
components [22]. Methyl helicterate and helicteric acid (HA) are the compounds present in the greatest concentration and have been considered as the characteristic and effective constituents in HT. Our pilot study showed that HT had a significant anti-inflammation activity since it downregulated IL-6 level on 2,4,6-trinitrobenzenesulfonic acid- (TNBS-) induced ulcerative colitis (UC) in mice [23]. Since ILs (especially IL-6) play a crucial role in NF-κB and STAT3 signaling pathways [9,12], according to our previous findings above we hypothesized that the antitumor activity of triterpenes from HT could be due to their role in both these two pathways and their crosstalk.

In the present study, we demonstrated that helicteric acid (HA), oleanic acid (OA), and betulinic acid (BA), three triterpenes from HT, possessed anti-CRC effects through decreasing inflammation, inhibiting cell proliferation, and promoting apoptosis of HT-29 cells through their action on both NF-κB and STAT3 pathways.

2. Materials and Methods

2.1. Chemicals. In our pilot study methyl helicterate, one of the chemical compounds present in HT, could only be dissolved in DMSO over 5‰, which is a level that could induce significant toxic effects and cell-cycle delay on HT-29 cells. Therefore, helicteric acid (HA), oleanic acid (OA), and betulinic acid (BA) were selected for our experiments and extracted from HT according to our previous study [24]. The chemical structures of HA, OA, and BA are shown in Figure 1. All the chemicals were dissolved in DMSO to prepare the 10 mM stocks. Recombinant human IL-6 (PeproTech, Rocky Hill, NJ, USA) was dissolved in 1x PBS containing 0.1% BSA to prepare a 10^7 ng/mL stock. Lipopolysaccharide (LPS, Sigma-Aldrich, Missouri, USA) was dissolved in 1x PBS to prepare a 10^2 μg/mL stock. All the stocks were stored at −20°C.

2.2. Cell Culture. HT-29 carcinoma cell line was kindly provided by the College of Life Science and Technology, Jinan University. Cells were cultured in a 5% CO₂ atmosphere with 100% humidity at 37°C, in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (Gibco, Grand Island, NY, USA), 50 units/mL penicillin, 50 mg/mL streptomycin, and 2 mmol/L L-glutamine. Cells were harvested using 0.25% trypsin (Gibco, Grand Island, NY, USA) and 1 mmol/L EDTA.

2.3. Cell Viability Measurement. HT-29 cells were seeded in 96-well plates at a density of 5 × 10^3 cells/well, in 100 μL cell culture medium per well, and incubated for 24 h. Thereafter, the culture medium was replaced with a fresh one containing drugs (HA and BA at increasing doses such as 1, 5, 10, 25, 50, and 100 μM; OA at 1, 10, 50, 100, 200, and 300 μM), and cells were allowed to grow for another 48 or 72 h. Total cell number was counted and the viability was evaluated using Cell Counting Kit-8 (CCK-8, Dojindo, Tokyo, Japan) according to the kit instructions. CCK-8 (10 μL/well) solution was added and incubated for 2 h, and the absorbance was measured at 450 nm using Multiskan FC microplate photometer (ThermoFisher, Rockford, IL, USA). The results are representative of three independent experiments in triplicate.

2.4. Apoptosis Assay. HT-29 cells were seeded in 6-well plates at a density of 5 × 10^4 cells/well, in 2 mL cell culture per well. Cells were harvested at 48 h and 72 h after the drug treatment (HA and BA at 1, 5, 10, and 25 μM; OA at 1, 10, 50, and 100 μM) and resuspended in cold PBS for analysis. Apoptosis assay was performed using the BD Pharmingen® FITC Annexin V Apoptosis Detection Kit (BD Biosciences, San Jose, CA, USA) according to the manufacturer’s instructions. Data were obtained and analyzed using BD FACS Calibur flow cytometry (BD Biosciences).

2.5. Measurement of IL-6 Release from HT-29 Cells. HT-29 cells in 6-well plates (2 × 10⁵ cells/well, 2 mL per well) were incubated with drugs (HA and BA at 10 and 25 μM; OA at 50 and 75 μM) for 1 h prior to stimulation with LPS (1 μg/mL) for 24 h. At the end of the experiment, the culture supernatants were collected and centrifuged at 3,000 × g at 4°C for 10 min to remove any cell debris. IL-6 levels in the media were measured by ELISA kits (Pierce-Endogen, Rockford, IL, USA) according to the manufacturer’s instructions.

2.6. Western Blot Analysis. HT-29 cells were seeded in 6-well plates at a density of 5 × 10⁴ cells/well in 2 mL cell culture per well. Cells were treated with HT extracts at different
27. Quantitative PCR. HT-29 cells were seeded in 6-well plates at a density of \(5 \times 10^5\) cells/well in 2 mL cell culture per well. Cells were treated with HT extracts at different concentrations (HA and BA at 1, 10, and 25 \(\mu\)M; OA at 1, 50, and 250 \(\mu\)M) for 4 h prior to stimulation with LPS for 30 min. Total RNA was extracted from cells using Trizol reagent (Invitrogen, Carlsbad, CA, USA). RNA was reverse-transcribed into cDNA using PrimeScript II RT reagent (Invitrogen, Carlsbad, CA, USA). RT-qPCR was performed using a LightCycler 480 Real-Time PCR System (Roche). The PCR reaction was carried out as follows: 95°C for 5 sec, 35 cycles at 95°C for 5 sec, and 60°C for 31 sec; and the dissociation stage was as follows: 95°C for 15 sec, 60°C for 1 min, and 95°C for 15 sec. The primers used for qPCR, designed by and purchased from Takara, were the following: cyclin D1 (CCND1), forward: \(5'\)-GTTCCACCTGAGCCTGTTTTC-3' and reverse: \(5'\)-GTGGTCATCAAGGCTGTTTAC-3'; c-Myc, forward: \(5'\)-GAGGGTCTACACACGAGA-3' and reverse: \(5'\)-TGGTCATCAAGTGTTCACC-3'; BCL-xL, forward: \(5'\)-CTGGGTCCCATACGACCATCTG-3' and reverse: \(5'\)-TGAGGACGCTAGCCATATAA-3'; GAPDH, forward: \(5'\)-GCACGTCAAGGGCTGAGAC-3' and reverse: \(5'\)-TGGTGAGACGCCATGGTA-3'. All reactions were performed in triplicate. Relative gene expression was determined using the \(2^{-\Delta\Delta CT}\) method, using GAPDH as the endogenous reference gene.

2.8. Statistical Analysis. Statistical analysis was performed using GraphPad Prism Version 5.01. Data are expressed as means ± standard deviation (SD). The significance of the differences between groups was estimated by one-way ANOVA, adjusting for repeated measures with Dunnett's multiple comparison tests. \(P < 0.05\) was considered statistically significant.

3. Results

3.1. HT Extracts Inhibit Proliferation and Induce Apoptosis in HT-29 Cell Line. Our results showed that HT extracts could markedly inhibit HT-29 cells growth in a dose-dependent manner (Figures 2(a)–2(c)). The IC50 at 48 h was ~10 \(\mu\)M for HA, ~10 \(\mu\)M for BA, and ~2 \(\mu\)M for OA (\(n = 5\), \(P < 0.05\)). However, the IC50 at 72 h did not show remarkable differences compared to that at 48 h.

In addition, HT extracts could induce HT-29 cells apoptosis in a dose-dependent manner (Figures 2(d)–2(f)). The apoptotic rate was significantly increased from ~5% onward for HA and BA and from ~10 \(\mu\)M onward for OA at 48 or 72 h (\(n = 5\), \(P < 0.05\)) compared with the untreated control cells. The results suggested that HT extracts were capable of inhibiting proliferation and inducing apoptosis in HT-29 tumor cells.

3.2. HT Extracts Inhibit IL-6 Release from HT-29 Cell Line. HA at 10 \(\mu\)M and 25 \(\mu\)M represented the concentrations inducing an IL-6 decrease of ~20% and ~40%, respectively, on HT-29 cells; BA at 10 \(\mu\)M and 25 \(\mu\)M, ~25% and ~55%, respectively; OA at 50 \(\mu\)M and 75 \(\mu\)M, ~15% and ~35%, respectively (\(n = 6\), \(P < 0.05\)) (Figure 2(g)).

3.3. HT Extracts Inhibit Apoptotic-Related Genes Expression in HT-29 Cell Line. We additionally investigated the effect of triterpenes on genes modulating the proliferation and apoptosis of tumor cells by RT-qPCR. Our results showed that HT extracts significantly blocked c-Myc, CCND1, and BCL-xL gene expression, markedly decreased from ~10 \(\mu\)M onward for HA, from ~10 \(\mu\)M for BA, and from ~50 \(\mu\)M for OA (\(n = 6\), \(P < 0.05\)) (Figures 3(a)–3(c)). The genes mentioned are also the downstream genes of NF-kB and STAT3 signaling pathway and they are related to NF-kB and STAT3 phosphorylation.

3.4. HT Extracts Inhibit LPS-Induced NF-kB Signaling Pathways. HT extracts treatment attenuated IKK/NF-kB pathway in HT-29 cells. The results indicated that HT extracts at high concentration could clearly inhibit LPS-induced IKK, IkB,
Figure 2: Treatment with HT extracts inhibits cell proliferation and induces apoptosis. (a–c) Cells were treated with HT extracts at the indicated concentrations for 48 or 72 h and CCK-8 cell proliferation assay was performed (n = 5/group). (d–f) Cells were treated with HT extracts at the indicated concentrations for 48 or 72 h and the percentage of apoptotic cells was determined by flow cytometry using Annexin V/PI staining (n = 5/group). (g) Cells were treated with HT extracts at the indicated concentrations for 1 h prior to stimulation with LPS (1 μg/mL) for 24 h and IL-6 in the supernatants was determined by ELISA. Data are expressed as means ± SD. **P < 0.01 versus untreated control group.
and NF-κB p65 phosphorylation but did not affect IKK, IkB, and NF-κB p65 protein level in HT-29 cells (Figure 4(a)).

### 3.5. HT Extracts Inhibit IL-6-Induced STAT3 Signaling Pathways

HT extracts attenuated IL-6-induced phosphorylation of JAK/STAT in CRC cell line. However, JAK2 and STAT3 protein level did not change after HT extracts treatment. In addition, JAK2 and STAT3 phosphorylation were significantly raised in HT-29 cells after IL-6 stimulation (n = 3) (Figure 4(b)).

### 4. Discussion

CRC is one of the most common human cancers in China and worldwide. The normal colon epithelium switches into malignant tumor due to alterations in specific key genes [9, 25]. In CRC, cancer cells usually become addicted to inflammatory stroma. Then, it progresses as metastasized untreatable cancer. Chronic inflammation may be involved in all steps of CRC development, such as initiation, promotion, and progression, and appears to play a chief role in tumor promotion and progression [12, 26–29].

Tumor microenvironment and its signaling pathways are considered as attractive targets for cancer prevention and therapy. The inflammatory cytokines, such as TNF-α, IL-6, and IL-1β, and the transcription pathways related to them [30, 31], especially NF-κB and STATs, are considered as potential targets for anti-CRC therapy [11, 13, 32–36].

Herbal phytochemicals consist of a wide variety of biologically active chemical constituents that are ubiquitous in plants, many of which have been reported to have anti-CRC
6 Evidence-Based Complementary and Alternative Medicine

properties [11, 37, 38]. Among them, HT possesses anti-inflammatory effects and potential therapeutic properties against CRC. However, little is known on the effects of HT extracts and their mechanism of action.

An enormous amount of data strongly demonstrated that inhibition of NF-κB signaling could be potentially effective in suppressing inflammation during tumor progression [35, 36]. In colon cancer cells, NF-κB is always constitutively activated and contributes to enhancing proliferation and evasion of apoptosis [13, 39, 40]. In this study, we used LPS-stimulated HT-29 cells as an in vitro CRC model and we observed that pretreatment with HT extracts suppressed LPS-triggered phosphorylation of IKK, IκB, and NF-κB, with HA showing these effects in a dose-dependent manner. These findings suggested that the triterpenes from HT inhibited LPS-induced production of the proinflammatory cytokine IL-6 by blocking, at least in part, NF-κB activation and subsequent transcription.

Recently, many studies showed that STAT3 pathway is involved in inflammation, proliferation, invasion, and migration of tumor cells [6, 32]. Constitutive activation of STAT3 is strongly associated with CRC development [41, 42]. Therefore, suppressing STAT3 activation to inhibit cell proliferation and/or promote apoptosis has been a leading target in the development of anti-CRC treatment. Patients with CRC often exhibit persistently activated STAT3, which could protect cells from apoptotic stimuli and promote cell-cycle progression in colorectal tumors [43]. Thereby these evidences suggest that interfering in the IL-6/JAK/STAT3 pathway could be a new therapeutic strategy for CRC treatment. Our result showed that HT extracts inhibited proliferation and induced apoptosis of HT-29 tumor cell line. We also found that they suppressed IL-6-induced phosphorylation of JAK2 in HT-29 cells, which is in accordance with the decreased phosphorylation of STAT3.

Both NF-κB and STAT3 play central roles in inflammatory cancers, especially in CRC [12, 14]. At present, an enormous amount of data strongly highlighted that inhibition of both NF-κB and STAT3 signaling, which are usually persistently activated in malignant tumors, could be potentially effective in suppressing inflammatory progression in cancers [44]. Our present findings indicated that triterpenes from HT could suppress activation of both IKK/NF-κB and JAK2/STAT3 pathway. Moreover, we found that HT extracts attenuated the expression of c-Myc, cyclin D1, and BCL-xL, which are important genes mediating proliferation and apoptosis, and they are also the downstream gene targets of NF-κB and STAT3. Thus HT extracts exerted their antitumor effects on HT-29 cells by suppressing inflammation and inhibiting proliferation.

However, there are still some important questions that should be elucidated. For example, although our previous study indicated that HT showed less effect on healthy mouse [23], the effects of HT extracts on normal human cells need to be investigated. Furthermore, many recent studies suggest that STAT3 could directly interact with the NF family member RELA in the nucleus, thereby contributing to CRC inflammation and malignant progression [45]. This event could persistently activate STAT3 and NF-κB, thus coregulating many oncogenic and inflammatory genes [46]. Hence, the exact anti-CRC mechanism of this traditional Chinese medicinal herb on NF-κB and STAT3 signaling needs further investigation.

5. Conclusion

Overall, our study demonstrated the antitumor activity of triterpenes from HT, indicating that they might be considered as potential therapeutic agents to combat CRC.

Competing Interests

The authors declare that there are no competing interests regarding the publication of this paper.
Acknowledgments

The authors will gratefully thank Dr. Nangsong Xia and Dr. Peng Zhang (Akeso Biopharma, Zhongshan, China) for the flow cytometry assays. This work was supported by the Guangdong Provincial Natural Science Foundation (no. 2016A030313366), the Zhongshan City Science and Technology Program (no. 20132A162 and no. 2014A2FC245), and the special program of innovation platform construction for strategic emerging industry of Zhongshan city (no. 415S36): Protein Engineering and Antibody Drug Development Zhongshan Sub-Laboratory in Guangdong Province.

References

[1] R. Siegel, C. Desantis, and A. Jemal, "Colorectal cancer statistics, 2014," CA Cancer Journal for Clinicians, vol. 64, no. 2, pp. 104–117, 2014.

[2] T. Watanabe, M. Itabashi, Y. Shimada et al., "Japanese Society for Cancer of the Colon and Rectum (JSSCR) guidelines 2010 for the treatment of colorectal cancer," International Journal of Clinical Oncology, vol. 17, no. 1, pp. 1–29, 2012.

[3] A. T. Chan and E. L. Giovannucci, "Primary prevention of colorectal cancer," Gastroenterology, vol. 138, no. 6, pp. 2029–2043.e10, 2010.

[4] S. Liu, R. Zheng, M. Zhang, S. Zhang, X. Sun, and W. Chen, "Incidence and mortality of colorectal cancer in China, 2011," Chinese Journal of Cancer Research, vol. 27, no. 1, pp. 22–28, 2015.

[5] E. van Cutsem, B. Nordlinger, and A. Cervantes, "Advanced colorectal cancer: ESMO clinical practice guidelines for treatment," Annals of Oncology, vol. 21, supplement 5, pp. v93–v97, 2010.

[6] J. K. Dyson and M. D. Rutter, "Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?" World Journal of Gastroenterology, vol. 18, no. 29, pp. 3839–3848, 2012.

[7] J. Terzić, S. Grivennikov, E. Karin, and M. Karin, "Inflammation and colon cancer," Gastroenterology, vol. 138, no. 6, pp. 2101.e5–2114.e5, 2010.

[8] S. I. Grivennikov, F. R. Greten, and M. Karin, "Immunity, inflammation, and cancer," Cell, vol. 140, no. 6, pp. 883–899, 2010.

[9] L. Klampfer, "Cytokines, inflammation and colon cancer," Current Cancer Drug Targets, vol. 11, no. 4, pp. 451–464, 2011.

[10] H. Knüpf and R. Preiss, "Serum interleukin-6 levels in colorectal cancer patients—a summary of published results," International Journal of Colorectal Disease, vol. 25, no. 2, pp. 135–140, 2010.

[11] K. S. Siveen, S. Sikka, R. Surana et al., "Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors," Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, vol. 1845, no. 2, pp. 136–154, 2014.

[12] E. Elinav, R. Nowarski, C. A. Thaiss, B. Hu, C. Jin, and R. A. Flavell, "Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms," Nature Reviews Cancer, vol. 13, no. 11, pp. 759–771, 2013.

[13] H. J. Kim, N. Hawke, and A. S. Baldwin, "NF-κB and IKK as therapeutic targets in cancer," Cell Death and Differentiation, vol. 13, no. 5, pp. 738–747, 2006.

[14] J. Bollrath and F. R. Greten, "IKK/NF-κB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis," EMBO Reports, vol. 10, no. 12, pp. 1334–1339, 2009.

[15] J. Khazir, B. A. Mir, L. Pilcher, and D. L. Riley, "Role of plants in anticancer drug discovery," Phytochemistry Letters, vol. 7, no. 1, pp. 173–181, 2014.

[16] M.-H. Teiten, F. Gaascht, M. Dicato, and M. Diederich, "Anti-cancer bioactivity of compounds from medicinal plants used in European medieval traditions," Biochemical Pharmacology, vol. 86, no. 9, pp. 1239–1247, 2013.

[17] G. M. Cragg and D. J. Newman, "Plants as a source of anti-cancer agents," Journal of Ethnopharmacology, vol. 100, no. 1-2, pp. 72–79, 2005.

[18] M.-H. Pan, C.-M. Chen, S.-W. Lee, and Z.-T. Chen, "Cytotoxic triterpenoids from the root bark of Helicteres angustifolia," Chemistry and Biodiversity, vol. 5, no. 4, pp. 565–574, 2008.

[19] Q. Huang, R. Huang, L. Wei et al., "Antiviral activity of methyl helicerate isolated from Helicteres angustifolia (Sterculiaceae) against hepatitis B virus," Antiviral Research, vol. 100, no. 2, pp. 373–381, 2013.

[20] W. Chen, W. Tang, L. Lou, and W. Zhao, "Pregnane, coumarin and lupane derivatives and cytotoxic constituents from Helicteres angustifolia," Phytochemistry, vol. 67, no. 10, pp. 1041–1047, 2006.

[21] X. Lin, R. Huang, S. Zhang et al., "Methyl helicerate protects against CCl4-induced liver injury in rats by inhibiting oxidative stress. NF-κB activation, Fas/FasL pathway and cytochrome P4502E1 level," Food and Chemical Toxicology, vol. 50, no. 10, pp. 3413–3420, 2012.

[22] Y.-S. Chang, Y.-R. Ku, J.-H. Lin, K.-L. Lu, and L.-K. Ho, "Analysis of three lupane type triterpenoids in Helicteres angustifolia by high-performance liquid chromatography," Journal of Pharmaceutical and Biomedical Analysis, vol. 26, no. 5-6, pp. 849–855, 2001.

[23] Y.-Q. Gao, D. Su, Y. Hu, H. Lin, W.-X. Zhang, and W.-B. Dai, "Effect of Helicteres angustifolia on rats with ulcerative colitis," Journal of Chinese Medicinal Materials, vol. 36, no. 4, pp. 597–600, 2013.

[24] Y. Q. Gao, D. Su, Y. G. Liang, T. Y. Zhang, and Q. X. Mei, "Study on triterpenoids from Helicteres angustifolia by high-speed countercurrent chromatography," Zhong YAO Cai, vol. 39, no. 5, pp. 1053–1056, 2013.

[25] R. Kalluri and R. A. Weinberg, "The basics of epithelial-mesenchymal transition," Journal of Clinical Investigation, vol. 119, no. 6, pp. 1420–1428, 2009.

[26] S. I. Grivennikov and M. Karin, "Inflammation and oncogenesis: a vicious connection," Current Opinion in Genetics & Development, vol. 20, no. 1, pp. 65–71, 2010.

[27] R. Medzhitov, "Origin and physiological roles of inflammation," Nature, vol. 454, no. 7203, pp. 428–435, 2008.

[28] A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, "Cancer-related inflammation," Nature, vol. 454, no. 7203, pp. 436–444, 2008.

[29] D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation," Cell, vol. 144, no. 5, pp. 646–674, 2011.

[30] W.-W. Lin and M. Karin, "A cytokine-mediated link between innate immunity, inflammation, and cancer," The Journal of Clinical Investigation, vol. 117, no. 5, pp. 1173–1183, 2007.

[31] B. Ancrile, K.-H. Lim, and C. M. Counter, "Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis," Genes and Development, vol. 21, no. 14, pp. 1714–1719, 2007.
[32] H. Yu, D. Pardoll, and R. Jove, "STATs in cancer inflammation and immunity: a leading role for STAT3," *Nature Reviews Cancer*, vol. 9, no. 11, pp. 798–809, 2009.

[33] Y. Ben-Neria and M. Karin, "Inflammation meets cancer, with NF-κB as the matchmaker," *Nature Immunology*, vol. 12, no. 8, pp. 715–723, 2011.

[34] M. Karin and F. R. Greten, "NF-κB: linking inflammation and immunity to cancer development and progression," *Nature Reviews Immunology*, vol. 5, no. 10, pp. 749–759, 2005.

[35] E. Pikarsky, R. M. Porat, I. Stein et al., "NF-κB functions as a tumour promoter in inflammation-associated cancer," *Nature*, vol. 431, no. 7007, pp. 461–466, 2004.

[36] F. R. Greten, L. Eckmann, T. F. Greten et al., "IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer," *Cell*, vol. 118, no. 3, pp. 285–296, 2004.

[37] S. Fletcher, J. A. Drewry, V. M. Shahani, B. D. G. Page, and P. T. Gunning, "Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein," *Biochemistry and Cell Biology*, vol. 87, no. 6, pp. 825–833, 2009.

[38] S. H. Yang, D. B. Khadka, S. H. Cho et al., "Virtual screening and synthesis of quinazolines as novel JAK2 inhibitors," *Bioorganic and Medicinal Chemistry*, vol. 19, no. 2, pp. 968–977, 2011.

[39] N. D. Perkins, "The diverse and complex roles of NF-κB subunits in cancer," *Nature Reviews Cancer*, vol. 12, no. 2, pp. 121–132, 2012.

[40] N. Sasaki, T. Morisaki, K. Hashizume et al., "Nuclear factor-κB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue," *Clinical Cancer Research*, vol. 7, no. 12, pp. 4136–4142, 2001.

[41] S. Grivennikov, E. Karin, J. Terzic et al., "IL-6 and Stat3 Are required for survival of intestinal epithelial cells and development of colitis-associated cancer," *Cancer Cell*, vol. 15, no. 2, pp. 103–113, 2009.

[42] J. Bollrath, T. J. Phesse, V. A. von Burstin et al., "gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis," *Cancer Cell*, vol. 15, no. 2, pp. 91–102, 2009.

[43] F. M. Corvinus, C. Orth, R. Moriggl et al., "Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth," *Neoplasia*, vol. 7, no. 6, pp. 545–555, 2005.

[44] S. Shalapour and M. Karin, "Immunity, inflammation, and cancer: an eternal fight between good and evil," *The Journal of Clinical Investigation*, vol. 125, no. 9, pp. 3347–3355, 2015.

[45] M. Wieczorek, T. Ginter, P. Brand, T. Heinzel, and O. H. Krämer, "Acetylation modulates the STAT signaling code," *Cytokine and Growth Factor Reviews*, vol. 23, no. 6, pp. 293–305, 2012.

[46] J. Bromberg and T. C. Wang, "Inflammation and cancer: IL-6 and STAT3 complete the link," *Cancer Cell*, vol. 15, no. 2, pp. 79–80, 2009.